RENAL DENERVATION FOR HYPERTENSION
Hypertension program development
Broaden your approach to hypertension with a highly focused program that includes the Symplicity™ blood pressure procedure.
Teaming up to take control of hypertension
Hypertension has been managed with lifestyle changes and medications, yet certain patients continue to fight to control their hypertension. Building a successful hypertension program allows you to focus your efforts and drive greater change.
80%
of hypertension patients
do not have their blood
pressure under control.1
50%
of hypertension patients become nonadherent to their medication within one year.2
Hypertension is a major cause of premature death worldwide.1
Three steps to get started
Here are three steps you can take right now to build or enhance a dedicated hypertension program.
1. Assess the opportunity.
The Symplicity™ blood pressure procedure is proven to provide significant, safe and sustained blood pressure reduction in the presence, and absence of medications,3–7 expanding your ability to treat hypertension.
2. Create a care pathway.
Promote blood pressure reduction by establishing a comprehensive treatment care pathway that considers global guidelines for the Symplicity™ blood pressure procedure.
3. Guide patient choices.
Engage and educate patients on hypertension management and control.
The experts agree.
European Society of Hypertension (ESH) guidelines recommend renal denervation for uncontrolled hypertension patients.8
Renal denervation, including the Symplicity™ blood pressure procedure, is recommended by the ESH and endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH), as a safe and effective complementary hypertension treatment strategy. In addition to the ESH Guidelines, renal denervation is globally recognized by several society publications including the European Society of Cardiology (ESC-EAPCI) consensus statement.8,9
Three pillars of hypertension treatment
The two most common pillars of hypertension care are lifestyle modifications and medications. Today, there is a third pillar available for treating hypertension: the Symplicity™ blood pressure procedure.
Lifestyle modifications
improve overall health.
Medications
help reduce blood pressure.
Symplicity™ blood pressure procedure
reduces blood pressure in patients who take antihypertensive medication and those who do not.3–7
Educate your patients.
Use our patient-friendly resources to provide an overview of hypertension, its health risks, and why the Symplicity™ blood pressure procedure might be the right choice.
1. World Health Organization. 16 March 2023.
2. Jung O, Gechter JL. Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Hypertension. 2013;31(4):766–774. doi: 10.1097/HJH.0b013e32835e2286.
3. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham- controlled trial. Lancet. 2020;395(10234):1444–1451. doi: 10.1016/S0140-6736(20)30554-7.
4. Kandzari D, Townsend R, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.
5. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10234):1401–1410. doi: 10.1016/S0140-6736(22)00455-X.
6. Mahfoud F, et al. Outcomes following radiofrequency renal denervation according to antihyptensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. EuroPCR 2023.
7. Mahfoud F, Mancia G, Schmieder RE, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the global SYMPLICITY registry DEFINE. Hypertension. 2023;80(8):1759–1770. doi: 10.1161/HYPERTENSIONAHA.123.21283.
8. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480.
9. Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44(15):1313–1330. doi: 10.1093/eurheartj/ehad054.